Company Search
CEO Interview
Drive With Dynacor Video Series
TSX_DNG on 2012-05-17 10:38Dynacor has released a new video series called the "Drive With Dynacor". http://youtu.be/seFbg2CXt6U
NAI Blog
My Top Junior Oil Stock in the Permian Basin “Tight” Oil Play Keith Schaefer on 2012-04-26 07:40:54Part 2: The Permian Basin – Cline Shale Resource Play
Company News - Company Data
BioMarin Appoints Dan Spiegelman as Executive Vice President and Chief Financial Officer
Posted 2012-05-08 06:44NAI Editing
announced today the appointment of Dan Spiegelman as Executive Vice President and Chief Financial Officer (CFO). Mr.BioMarin Pharmaceutical Announced Financial Results for The First Quarter of 2012
Posted 2012-04-26 06:42NAI Editing
today announced financial results for the first quarter of 2012.BioMarin Completes Enrollment for Phase 3 Trial for GALNS for the Treatment of MPS IVA
Posted 2012-03-08 01:21NAI Editing
today announced that enrollment is complete for the pivotal Phase 3 trial for N-acetylgalactosamine 6-sulfatase (GALNS or BMN-110), intended for the treatment of the lysosomal storage disorder MucopolBioMarin Announces Chief Financial Officer Jeffrey Cooper to Leave the Company
Posted 2012-02-21 00:37NAI Editing
announced today that Jeffrey Cooper, Senior Vice President and Chief Financial Officer, plans to leave the company.BioMarin Announces IND for BMN-111 for Achondroplasia is Active
Posted 2012-01-03 01:58NAI Editing
announced today that the Investigational New Drug (IND) application for BMN-111, an analog of C-type Natriuretic Peptide (CNP), for achondroplasia is active.BioMarin Receives Positive Opinion from European Regulatory Authorities for Expanded Biologics Manufacturing Facility
Posted 2011-12-19 00:36NAI Editing
announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval for the company's manufacturing facility expansion in NovBioMarin Announces FDA Approval of Expanded Biologics Manufacturing Facility
Posted 2011-11-28 01:29NAI Editing
announced today that it has received approval from the U.S. Food and Drug Administration (FDA) for the manufacturing facility expansion in Novato, CA.BioMarin Agrees to Acquire Biologics Manufacturing Plant in Ireland from Pfizer
Posted 2011-06-23 10:59NAI500 Admin
announced today that it has entered into a definitive agreement to acquire a bulk biologics manufacturing plant from Pfizer, located in Shanbally, Cork, Ireland.BioMarin Initiates Pivotal Phase 3 Trial for GALNS for the Treatment of MPS IVA
Posted 2011-02-01 14:35NAI500 Admin
announced today that it has initiated a pivotal Phase 3 trial for N-acetylgalactosamine 6-sulfatase (GALNS or BMN 110), intended for the treatment of the lysosomal storage disorder MucopolysaccharidosBioMarin Initiates Phase 1/2 Trial for BMN 701 for the Treatment of Pompe Disease
Posted 2011-01-19 10:26NAI500 Admin
announced today that it has initiated a Phase 1/2 trial for BMN 701, a novel fusion protein of insulin-like growth factor 2 and acid alpha glucosidase (IGF2-GAA) in development for the treatment of Po
Posted 2012-05-08 06:44
NAI Editingannounced today the appointment of Dan Spiegelman as Executive Vice President and Chief Financial Officer (CFO). Mr.BioMarin Pharmaceutical Announced Financial Results for The First Quarter of 2012
Posted 2012-04-26 06:42
NAI Editingtoday announced financial results for the first quarter of 2012.BioMarin Completes Enrollment for Phase 3 Trial for GALNS for the Treatment of MPS IVA
Posted 2012-03-08 01:21
NAI Editingtoday announced that enrollment is complete for the pivotal Phase 3 trial for N-acetylgalactosamine 6-sulfatase (GALNS or BMN-110), intended for the treatment of the lysosomal storage disorder MucopolBioMarin Announces Chief Financial Officer Jeffrey Cooper to Leave the Company
Posted 2012-02-21 00:37
NAI Editingannounced today that Jeffrey Cooper, Senior Vice President and Chief Financial Officer, plans to leave the company.BioMarin Announces IND for BMN-111 for Achondroplasia is Active
Posted 2012-01-03 01:58
NAI Editingannounced today that the Investigational New Drug (IND) application for BMN-111, an analog of C-type Natriuretic Peptide (CNP), for achondroplasia is active.BioMarin Receives Positive Opinion from European Regulatory Authorities for Expanded Biologics Manufacturing Facility
Posted 2011-12-19 00:36
NAI Editingannounced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval for the company's manufacturing facility expansion in NovBioMarin Announces FDA Approval of Expanded Biologics Manufacturing Facility
Posted 2011-11-28 01:29
NAI Editingannounced today that it has received approval from the U.S. Food and Drug Administration (FDA) for the manufacturing facility expansion in Novato, CA.BioMarin Agrees to Acquire Biologics Manufacturing Plant in Ireland from Pfizer
Posted 2011-06-23 10:59
NAI500 Adminannounced today that it has entered into a definitive agreement to acquire a bulk biologics manufacturing plant from Pfizer, located in Shanbally, Cork, Ireland.BioMarin Initiates Pivotal Phase 3 Trial for GALNS for the Treatment of MPS IVA
Posted 2011-02-01 14:35
NAI500 Adminannounced today that it has initiated a pivotal Phase 3 trial for N-acetylgalactosamine 6-sulfatase (GALNS or BMN 110), intended for the treatment of the lysosomal storage disorder MucopolysaccharidosBioMarin Initiates Phase 1/2 Trial for BMN 701 for the Treatment of Pompe Disease
Posted 2011-01-19 10:26
NAI500 Adminannounced today that it has initiated a Phase 1/2 trial for BMN 701, a novel fusion protein of insulin-like growth factor 2 and acid alpha glucosidase (IGF2-GAA) in development for the treatment of Po